A PERFECT MATCH WITH NGS

THE IDYLLA™ PLATFORM

BIOCARTIS

ULTRA-RAPID IDYLLA™ TESTING COMPLEMENTS NGS

Despite the clear advantages of comprehensive molecular profiling by next-generation sequencing (NGS), the associated testing complexity often translates into long turnaround times (TAT). Rapid mutation assessment through alternate methods remains critical for key genomic alterations. The Idylla™ system facilitates ultra-rapid assessment of key molecular markers which can be seamlessly integrated into virtually any laboratory workflow and used concurrently with NGS.

CURRENT MOLECULAR TESTING OPTIONS IN ONCOLOGY



THE BEST OF BOTH WORLDS: ULTRA-RAPID RESULTS OF MOST COMMON MUTATIONS COMBINED WITH COMPREHENSIVE MOLECULAR PROFILING

OPTIMIZED TESTING EFFICIENCY IN LARGE LABORATORY SETTINGS - REAL WORLD EXAMPLES

LUNG CANCER TESTING IN A LARGE ACADEMIC CENTER, NEW YORK, NY[6]



IDYLLA™ IMPACT

- Turnaround time for rapid EGFR testing reduced from 9 days to 1-3 days
- Simple workflow allows implementation of ultra-rapid testing solution without requiring additional resources
- Flexible platform is able to handle the variety of different sample types coming into the lab
- Use of minimal material allows further testing by NGS assays

CRC TESTING IN A LARGE LABORATORY, DANVILLE, PA[7]



IDYLLA™ IMPACT

- Turnaround time for RAS/BRAF testing reduced from 4-7 days to 1-2 days
- 1 FTE freed up due to full-automated testing nature
- Internal test menu expanded

IDYLLA™ AND NGS - A PERFECT MATCH

REDUCED TIME TO RESULT FOR KEY BIOMARKERS

- On demand testing with short assay turnaround times
- Minimal sample manipulation

MINIMAL ADDITIONAL RESOURCES NEEDED

- Fully automated walk-away system
- Only 2 min hands-on time per sample

REDUCED COST

- Cost-effective even for smaller sample volumes, no batching needed
- Only a subset of samples has to be reflexed to NGS

MINIMAL SAMPLE REQUIREMENTS & VERSATILE SAMPLE TYPES

- Various types possible, including FFPE, fresh tissue, plasma, DNA[8,9]
- Reliable results even for small & challenging samples

REFERENCES

(1) Dagogo-Jack I et al. (2018), JCO Precision Oncology; Epub 2018 Jul 24.
(2) Mackinnon A et al. (2019) Journal of Molecular Diagnostics; 21(5): 862-872.
(3) Ghigna M et al. (2018) Journal of Thoracic Disease; 10(7): 4653-4658.
(4) Al-Turkmani et al. (2018) Modern Pathology; 32 Abstract #581.
(5) Brohawn DG et al. (2019) Journal of Diagnostic Techniques and Biomedical Analysis; 7:2.
(6) Nafa et al (2019) Journal of Molecular Diagnostics; 21(6), Abstract #ST028.
(7) Ding Y 2019, presented at the Biocartis Corporate Workshop, AMP Annual Meeting 2019, www.biocartis.com/en-US/publications.
(8) Arcila M et al. (2018) Journal of Molecular Diagnostics; 20(6) Abstract #ST027.
(9) Al-Turkmani, R et al. (2018) Clinical Chemistry; 64(5): 865-866.

Contact details
Biocartis US Inc.
30 Montgomery Street, 9th Floor, Suite 970
Jersey City, NJ 07302
1-844-4-IDYLLA (1-844-443-9552)
www.biocartis.com/US
customerserviceUS@biocartis.com

Follow us on

For Research Use Only. Not for use in diagnostic procedures.

BIOCARTIS
biocartis.com/us

US.BROO6.EN.N.122019